Patient-Reported Outcomes: Current Perspectives and Future Directions

Clinical Therapeutics

Volumn 35, Issue 4, 2013, Pages 399-401

  Coon, Cheryl D ^a   McLeod, Lori D ^a  

^a RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; MEDICAL DECISION MAKING; PAIN; PAIN ASSESSMENT; PATIENT ATTITUDE; QUALITY OF LIFE;

HUMANS; SELF-ASSESSMENT; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84876336394     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.01.012     Document Type: Article

References (9)

1. Wilson I., Cleary P. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995, 273:59-65.
2. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims US Department of Health and Human Services, Accessed December 14, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.
3. Guidance for industry. Qualification process for drug development tools, October 2010 US Department of Health and Human Services, Accessed December 14, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf.
4. DeMuro C., Clark M., Mordin M., et al. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010. Value Health 2012, 15:443-448.
5. Gnanasakthy A., Mordin M., Clark M., et al. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health 2012, 15:437-442.
6. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products, January 2006 European Medicines Agency, Accessed December 14, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf.
7. Qualification of novel methodologies for drug development: guidance to applicants, January 2009 European Medicines Agency, Accessed December 14, 2012. http://www.emea.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004201.pdf.
8. Gnanasakthy A, Doward L, Clark M, et al. Concordance of PRO labeling claims between the FDA and EMA. Poster Presented at: the ISPOR 15th Annual European Congress; November 3-7, 2012; Berlin, Germany.
9. Patient-Centered Outcomes Research Institute. How we're funded Accessed December 14, 2012. http://www.pcori.org/how-were-funded.